Day: March 8, 2021

BOCA RATON, Fla, March 08, 2021 (GLOBE NEWSWIRE) — Sensus Healthcare, Inc. (NASDAQ: SRTS), a  medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, today announced that Joe Sardano, Chairman and Chief Executive Officer, will participate in three virtual investment conferences during the month of March, as follows:The H.C. Wainwright Global Life Sciences Virtual Conference with one-on-one meetings being held March 9-10, 2021The Virtual 33rd Annual Roth Conference with one-on-one meetings being held March 15- 17, 2021 in a live panel discussion titled, “Flipping the Switch to Profitability” to be held on March 16 at 10:00 a.m. Eastern timeThe Maxim Group Emerging Growth Virtual Conference being held March 17-18, 2021 with...

NEW YORK, March 08, 2021 (GLOBE NEWSWIRE) — Pzena Investment Management, Inc. (NYSE: PZN) today reported its preliminary assets under management as of February 28, 2021.AUM for month-end February 2021, month-end January 2021, and month-end February 2020 are listed below:Pzena Investment Management, Inc.Assets Under Management1($ billions)1 Numbers may be subject to rounding.About PzenaPzena Investment Management, LLC, the firm’s operating company, is a value-oriented investment management firm. Founded in 1995, Pzena Investment Management has built a diverse, global client base. More firm and stock information is posted at www.pzena.com.Forward-Looking StatementsThis press release may contain, in addition to historical information, forward-looking statements within the meaning of Section 27A of the Securities Act of 1933,...

SILICON VALLEY, Calif., March 08, 2021 (GLOBE NEWSWIRE) — AMD (NASDAQ:AMD) and Xilinx (NASDAQ:XLNX) announced today they have set a date for the Special Meetings of Stockholders to vote on the proposed acquisition of Xilinx by AMD. AMD and Xilinx stockholders of record as of the close of business on Feb. 10, 2021 will be entitled to vote at their respective Special Meetings, both of which will be held virtually on Wednesday, Apr. 7, 2021 at 9:30 a.m. Pacific Time.AMD and Xilinx filed a definitive joint proxy statement and prospectus with the U.S. Securities and Exchange Commission in connection with the proposed transaction. The AMD and Xilinx Boards of Directors each unanimously recommends that respective stockholders vote “FOR” the proposed acquisition and other proposals set forth in the definitive joint proxy statement and prospectus,...

CHARLOTTE, N.C., March 08, 2021 (GLOBE NEWSWIRE) — Glatfelter Corporation (NYSE: GLT) announced Dante Parrini, Chairman and Chief Executive Officer, and Samuel Hillard, Senior Vice President and Chief Financial Officer, will participate in the NYSE Materials Access Day investor conference on Tuesday, March 9, 2021. This conference is a virtual-only forum and attendance is by invitation-only.A copy of the slide presentation that will accompany management’s remarks will be available on the Company’s Investor Relations page at https://www.glatfelter.com/investors/webcasts-and-presentations/.About GlatfelterGlatfelter is a leading global supplier of engineered materials. The Company’s high-quality, innovative and customizable solutions are found in tea and single-serve coffee filtration, personal hygiene and packaging products as well...

TORONTO and MIAMI, March 08, 2021 (GLOBE NEWSWIRE) — Leading diversified professional services and investment management firm Colliers (NASDAQ and TSX: CIGI) today announced that its Colliers Engineering & Design (“Colliers E&D”) operating unit has acquired Bolton Perez & Associates (“BPA”), a Miami-based transportation engineering and design firm. The new addition will immediately rebrand as Colliers E&D and will be fully integrated into the rapidly growing business unit. Terms of the transaction were not disclosed.Founded in 1997 by Joaquin (“Jake”) Perez and John Bolton, BPA’s more than 30 engineers and other professionals provide specialty transportation and bridge design, as well as inspection services to state and municipal transportation authorities primarily in the state of Florida.“This acquisition is...

BEIJING, March 08, 2021 (GLOBE NEWSWIRE) — 17 Education & Technology Group Inc. (NASDAQ: YQ) (“17EdTech” or the “Company”), a leading education technology company in China with an “in-school + after-school” integrated model, today announced its unaudited financial results for the fourth quarter and the year ended December 31, 2020.Fourth Quarter 2020 Highlights1Net revenues were RMB486.8 million (US$74.6 million), representing a year-over-year increase of 153.1% from RMB192.3 million in the fourth quarter of 2019.Net revenues from online K-12 tutoring services were RMB467.5 million (US$71.6 million), representing a year-over-year increase of 163.5% from RMB177.4 million in the fourth quarter of 2019.Gross billings of online K-12 tutoring services2 (non-GAAP) were RMB579.2 million (US$88.8 million), representing a year-over-year...

Superior profile of novel anti-tau antibody PRX005 supports advancement for the potential treatment of Alzheimer’s diseaseNew analyses of prasinezumab continue to support potential disease modifying effect of prasinezumab in Parkinson’s disease; Roche expected to initiate Phase 2b PADOVA study in 2Q21Investor conference call and webcast scheduled for Thursday, March 11, at 4:30PM ETDUBLIN, Ireland, March 08, 2021 (GLOBE NEWSWIRE) — Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid and neurodegenerative diseases, will hold an investor webcast Thursday, March 11, at 4:30 PM ET to review three oral presentations made at The 15th International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD...

– Operating Income Improved to $7.7 Million from an Operating Loss of $0.4 Million;Net Income Improved to $3.5 Million from a Net Loss of $4.1 Million;Adjusted EBITDA More Than Quadrupled from Prior-Year Quarter– Company Issued New 8.25% Senior Secured Notes due 2028;Proceeds Used to Refinance Its Existing Debt, Retire Warrants to Purchase Approximately One Million Shares,and Fully Fund Its New Casino Hotel in Cripple Creek, Colorado– Construction of Augmented Cripple Creek Project has Restarted;New Casino Hotel is Expected to Open in the Fourth Quarter of 2022– Third Sports Wagering Provider Launched Operations in December 2020;Remaining Three “Skins” Expected to Begin Operations Shortly– As of February 28, 2021, Company Has Approximately $232 Million of Cash and Equivalents,Including $180 Million in a Construction...

Highlights for Fourth Quarter 2020:Revenues of $14.6 million, a 16% increase compared with $12.6 million for prior year;Adjusted EBITDA reached a new high of $4.0 million, compared with $2.1 million for prior year;Segment contribution from ImprimisRx reached $5.0 million for the fourth quarter of 2020;GAAP operating income increased to $2.6 million compared with $0.9 million for prior year; andGross margins steadied at 73%.NASHVILLE, Tenn., March 08, 2021 (GLOBE NEWSWIRE) — Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic-focused healthcare company, today announced results for the fourth quarter and year ended December 31, 2020. The Company also posted its fourth quarter Letter to Stockholders to the “Investors” section of its website, harrowinc.com.Total revenues were $14.6 million for the fourth quarter of 2020, a 16% increase...

ROCKVILLE, Md. and CHESTERBROOK, Pa., March 08, 2021 (GLOBE NEWSWIRE) — Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases, today announced recent business progress and year-end financial results for 2020.“Looking back, 2020 was a very productive and transformative year for Cerecor highlighted by swift transition post the merger with Aevi Genomic Medicine, improving the financial position of the company and initiating clinical trials across our pipeline,” said Mike Cola, Chief Executive Officer of Cerecor. “2021 started strong with positive Phase 2 data from CERC-002, our novel anti-LIGHT drug candidate in development for the treatment of COVID-19 ARDS. We have recently filed both Breakthrough Therapy and Fast Track...